PACTR201611001855404尚未招募未知
Interactive weekly mobile phone text messaging plus motivational interviewing in promotion of breastfeeding among women living with HIV
Moleen Zunza0 个研究点目标入组 84 人开始时间: 2016年11月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 45 Year(s)（—）
- 性别
- Female
入选标准
- •HIV-infected women
- •initiating breastfeeding soon after giving birth
- •18 years or older
- •ownership of a mobile phone
- •infants judged to be in good health who are discharged soon after delivery
排除标准
- •viral load > 400 copies/ml
- •formula feeding
- •pregnant with > 1 infant
- •birth weight < 2000
- •gestational age < 36 weeks
研究者
相似试验
进行中（未招募）
1 期
A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension.hypertensionEUCTR2008-002797-36-SKovartis Pharma Services AG230
进行中（未招募）
不适用
A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension.MedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionhypertensionEUCTR2008-002797-36-FRovartis Pharma Services AG230
进行中（未招募）
不适用
A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension.hypertensionEUCTR2008-002797-36-HUovartis Pharma Services AG230
已完成
4 期
Effect of insulin detemir and insulin glargine on blood glucose control in subjects with type 2 diabetesCTRI/2009/091/000161ovo Nordisk AS52
进行中（未招募）
1 期
A 20 week multi-national, open-labelled, randomised, three-group parallel trial comparing administration of insulin detemir morning, insulin detemir evening and NPH insulin evening as add-on to oral antidiabetic drug(s) in subjects with type 2 diabetesMedDRA version: 7.0Level: PTClassification code 10049746Type 2 DiabetesEUCTR2004-001461-18-ESovo Nordisk AS